Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.40 |
| ▸ | ABAT | P80404 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421523 | 1.00 | ALDH1A1 (0.49) | ALDH1A1ALDH1A3KDM4EPTGS2RAB9A | |
| SCHEMBL4310609 | 0.88 | KDM4E (0.48) | ALDH1A1ALDH1A3KDM4EPTGS2RAB9A | |
| SCHEMBL29957404 | 0.88 | KDM4E (0.48) | ALDH1A1ALDH1A3KDM4EPTGS2RAB9A | |
| SCHEMBL3784501 | 0.81 | KDM4E (0.50) | ALDH1A1ALDH1A3KDM4EPTGS2RAB9A | |
| SCHEMBL3783722 | 0.81 | KDM4E (0.50) | ALDH1A1ALDH1A3KDM4EPTGS2RAB9A | |
| SCHEMBL28947075 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4EPTGS2RAB9AALDH5A1 | |
| SCHEMBL6503621 | 0.79 | PTGS1 (0.34) | ALDH1A1ALDH1A3KDM4EPTGS2 | |
| SCHEMBL31317426 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4EPTGS2RAB9AALDH5A1 | |
| SCHEMBL26773854 | 0.78 | KDM4E (0.46) | ALDH1A1ALDH1A3KDM4EPTGS2RAB9A | |
| SCHEMBL1711479 | 0.78 | KDM4E (0.47) | ALDH1A1KDM4EPTGS2RAB9ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110357911-B | Brassinosteroid derivatization reagent and preparation method and application thereof | 武汉大学 | 2020-07-24 | — | — | CN | claimed |
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| EP-3946349-B1 | SR-1903 FOR THE TREATMENT OF INFLAMMATORY, INNATE IMMUNE RESPONSE OR AUTOIMMUNE DISORDERS | UNIV FLORIDA (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12370193-B2 | Method of inhibiting TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-07-29 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-21 | — | — | US | disclosed |
| WO-2019035899-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018081558-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES, BV (NL) | 2018-05-03 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
| CN-1468226-A | Biphenyl derivatives and their use as ppar-gamma receptor activators | �������о�����չ˽������˾ | 2004-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | ALDH1A1 1028/4885ALDH1A3 1409/4885KDM4E 2221/4885 |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR1, ACVR1B | ALDH1A1 589/4885ALDH1A3 2813/4885KDM4E 347/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | ALDH1A1 609/4885ALDH1A3 1769/4885KDM4E 43/4885 |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | ALDH1A1 378/4885ALDH1A3 786/4885KDM4E 3138/4885 |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | ALDH1A1 647/4885ALDH1A3 1902/4885KDM4E 1735/4885 |
| US-12370193-B2 | Method of inhibiting TREM-1 | DAPK3, DAPK1, GPR3 | ALDH1A1 3682/4885ALDH1A3 1420/4885KDM4E 3321/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | ALDH1A1 771/4885ALDH1A3 1292/4885KDM4E 49/4885 |
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | ALDH1A1 561/4885ALDH1A3 2657/4885KDM4E 1080/4885 |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | WEE1, WEE2, PARP1 | ALDH1A1 925/4885ALDH1A3 1678/4885KDM4E 2398/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | ALDH1A1 1225/4885ALDH1A3 1703/4885KDM4E 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.